D etailed characterization of resident T cells in tissues un-
dergoing chronic inflammation presents a number of difficulties, not the least being the inaccessibility of the target organ. T cells involved in autoimmune disease of the CNS (multiple sclerosis) and pancreas (type 1 diabetes) present extreme examples of this inaccessibility (1, 2) . In addition, studies of chronic inflammation and the characterization of the molecular players involved have primarily focused on protein-derived peptide Ags. However, T cell activation and pathogenesis can also be triggered by a wide variety of low molecular weight Ags, including metals, frequently resulting in allergic hyperreactivity (3, 4) and the ability of metals to induce T cell activation in a MHC-restricted manner has been clearly established (5) . Although several interesting models explaining this metal-induced activation of T cells have been proposed, a detailed understanding of the precise nature of the epitope recognized by metal-specific T cells remains in almost all cases unknown (6, 7) . Furthermore, the detailed immunological characteristics defining the T cell response to metals is extremely vague, and in the majority of cases a consensus is far from being established.
Chronic beryllium disease (CBD) 4 is an occupational disease caused by exposure to the metal beryllium (molecular weight ϭ 9), characterized by the formation of noncaseating granuloma and mononuclear cell infiltration into the lung (8, 9) . Immunological studies have suggested that CD4 ϩ T cells are important in the initiation and perpetuation of the beryllium-induced chronic inflammation (10, 11) . Recognition of beryllium by CD4 ϩ T cells in CBD patients appears to involve certain HLA class II molecules, and specific HLA-DP molecules have been associated with beryllium sensitization and CBD severity (12) (13) (14) . Beryllium-specific CD4 ϩ T cells have been found to express a Th1-type phenotype in response to beryllium sulfate (BeSO 4 ) (15, 16) , and nearly all bronchoalveolar lavage (BAL) T cells from patients with CBD exhibit an effector memory cell phenotype (17) (18) (19) . The development of granulomatous inflammation is associated with the accumulation of activated CD4 ϩ T cells in the BAL (20) . The majority of beryllium-specific CD4 ϩ T cells are compartmentalized in the lung, with up to 20 -30% of the BAL CD4 ϩ T cells being beryllium specific and expressing Th1-type cytokines upon beryllium exposure in culture (17) . In a number of CBD patients studied, the T cells showed oligoclonal expansion with particular TCRs specific for CBD (21) , and analysis of TCR expression on BAL CD4 ϩ T cells has revealed the presence of TCR motifs specific for beryllium-reactive T cells (22) . We have chosen to study CBD and beryllium-induced molecular changes in CD4 ϩ T cells both as a model of metal-induced T cell activation in the lung and as an opportunity to characterize resident CD4 ϩ T cells from tissues undergoing chronic inflammation. Our long-term goal is to map the cascade of events that control the resident T cell populations' behavior as a means of obtaining new insights focused on how to prevent this chronic inflammatory and eventually debilitating disease.
With regard to Ag-specific T cell activation, naive T cells appear to require two signaling events, TCR engagement with Ag/MHC and a second costimulatory signal, which is most frequently mediated by the engagement of CD28 on the T cell with its ligands B7-1 or B7-2, on APCs (23, 24) . The BAL beryllium-specific CD4 ϩ T cells are effector memory cells that proliferate and secrete cytokines after TCR engagement without an absolute requirement for CD28-mediated costimulation (25) . This result suggested either no dependence on costimulation or the involvement of a different costimulation pathway such as OX40/OX40 ligand (OX40L). OX40 (CD134), a membrane-bound member of the TNFR superfamily, is expressed primarily on activated CD4 ϩ T cells (26) . Following engagement of OX40 with OX40L expressed on the APC, OX40 delivers a costimulatory signal that leads to potent, proinflammatory effects (27, 28) . However, whether or not human beryllium-specific CD4 ϩ T cells expressed OX40 and, if so, whether the OX40/OX40L costimulatory pathway could play a role in beryllium-induced CD4 ϩ T cell activation has not been explored previously.
In the current study, we evaluated a beryllium-reactive T cell line from the BAL of a CBD patient for the level and the duration of T cell proliferation and cytokine secretion, MHC restriction, and changes in the expression of T cell adhesion molecules, activation markers, and costimulatory molecules upon stimulation with beryllium. These studies substantially enhance our understanding of the immunological features of beryllium-induced activation of BAL CD4
ϩ T cells and provide new data suggesting potential therapeutic avenues for intervention in CBD.
Materials and Methods

Generation of beryllium-specific BAL CD4 ϩ T cells and APCs
The BAL CD4 ϩ T cell line from a representative HLA-DP2 homozygous CBD patient was developed as previously described (29) . Briefly, the diagnosis of CBD was established using previously defined criteria, including a history of beryllium exposure, the presence of granulomatous inflammation upon lung biopsy, and a positive beryllium lymphocyte-proliferation test (30, 31) . The BAL cells from an HLA-DP2 homozygous CBD patient were collected and briefly stimulated with 10 M (1 ϫ 10 Ϫ5 M) BeSO 4 (Sigma-Aldrich) in the presence of EBV-transformed autologous APCs at a ratio of 1:1 (T:APC) for 3 days, followed by the addition of 10 ng/ml rIL-2 (R&D Systems) twice weekly. The induction of EBVtransformed APCs from patient's PBMC was achieved by using the methods as previously reported (32, 33) . HLA typing was performed by standard molecular techniques as previously described (29) .
BAL CD4 ϩ T cell line proliferation assay
The BAL CD4 ϩ T cell line was selected by stimulating BAL cells with 10 M BeSO 4 in the presence of irradiated (9000 rad) EBV-transformed autologous APCs at a ratio of 1:1 in culture medium of RPMI 1640 with 10% FBS supplemented with 2 mM L-glutamine,1 mM sodium pyruvate, 0.2 mM nonessential amino acids (Invitrogen Life Technologies), 100 g/ml penicillin G, and 100 g/ml streptomycin (Invitrogen Life Technologies) followed by the addition of 10 ng/ml rIL-2 twice weekly. The proliferation assay was performed using 4 ϫ 10 4 T cells/well in triplicate in 96-well U-bottom culture plates plus irradiated (9000 rad) EBV-transformed autologous APCs at a ratio of 1:1, alone or in the presence of BeSO 4 , at a concentration ranging from 0.2 to 80 M, for 3 days with 0.5 Ci [
3 H]thymidine (Amersham) incorporation for the last 6 h of the culture, before harvesting. The radioactivity was determined by a liquid scintillation counter 1205 Betaplate (Wallac) and proliferation was expressed by either stimulation index (experimental cpm Ϭ control cpm) or net cpm (experimental cpm Ϫ control cpm). Student's t test was used for determining statistical significance between different cpm (mean Ϯ SD) values. The transfected mouse L cell line DAP3(DP2) encoding HLA-DP2 genes was also used as APCs, irradiated (4500 rad) (33) , and cocultured with CD4 ϩ T cells at a ratio of 1:1 for 3 days, alone or in the presence of BeSO 4 , at the same concentration range as that used for autologous APCs. As irrelevant Ag controls, NiSO 4 (Sigma-Aldrich) and the myelin oligodendrocyte glycoprotein (MOG) 35 
Cytometric bead array (CBA) assay used to detect and quantify cytokine production
The CBA assay was performed using the human Th1/Th2 cytokine II CBA kit (catalogue no. 551809; BD Biosciences), which quantifies the following cytokines: IL-2, IL-4, IL-6, IL-10, IFN-␥, and TNF-␣. CBA cytokine quantification assay sensitivity for each cytokine is listed as follows: IL-2 (2.6 Ϯ 0.2 pg/ml), IL-4 (2.6 Ϯ 0.2 pg/ml), IL-6 (3.0 Ϯ 0.2 pg/ml), IL-10 (2.8 Ϯ 0.2 pg/ml), IFN-␥ (7.1 Ϯ 0.3 pg/ml), and TNF-␣ (2.8 Ϯ 0.2 pg/ml). To obtain an accurate value for absolute IFN-␥ production within the limits of the CBA system, a 1/25 dilution of culture supernatants was necessary. Briefly, 50 l of supernatant, 50 l of a mixture of capture beads, and 50 l of Th1/Th2 PE detection reagent were combined and incubated for 3 h at room temperature in the dark. The samples were thoroughly washed and subsequently resuspended in 200 l of wash buffer and analyzed by flow cytometry (FACScan). Standard curves were generated for each cytokine using a mixed bead standard to interpolate the concentration of cytokine in the supernatant in picograms per milliliter.
Blocking T cell response to beryllium by using mAbs and recombinant CTLA-4Ig
The purified forms of anti-OX40 (CD134), anti-OX40L (TNFS4 Ab), anti-CD28, anti-CTLA-4 (CD152), anti-HLA-DR, -DP, and -DQ were dialyzed against RPMI 1640 with three buffer changes to remove any potential cytotoxic sodium azide. All blocking Abs were subsequently tested in a proliferation assay with PBMCs stimulated with Con A as a control to verify that no residual sodium azide remained. In our mAb blocking proliferation assay, T cells were stimulated with 10 M BeSO 4 at 4 ϫ 10 R&D Systems) was prepared in aliquots of RPMI 1640/1% serum and ensured of noncytotoxicity in a Con A stimulation assay as described above for purified mAbs.
Results
Specificity and proliferation level of BAL CD4
ϩ T cells (Fig. 1A) . Use of a transfected mouse fibroblast cell line DAP3(DP2) encoding human HLA-DP2 (HLA-DPA1*0103/DPB1*0201) genes as APCs resulted in a maximal SI of 4ϫ, 70% lower than that induced by autologous APCs. In contrast, use of a transfected mouse fibroblast cell line DAP3(DP4) encoding the human HLA-DP4 gene (HLA-DPA1*0103/DPB1*0401; identical to HLA-DP2 except at residues 36, 55/56, and 69 within the ␤-1 domain) as APCs resulted in a maximal SI of only 2ϫ, 85% lower than that induced by autologous APCs, and no greater than that of T cells alone in the presence of BeSO 4 . The cells were highly specific for beryllium and showed virtually no proliferation to NiSO 4 or to an irrelevant Ag peptide, MOG peptide, which can bind with high affinity to HLA-DP2 (R. Meza-Romero, personal communication).
Potent secretion of IFN-␥ and TNF-␣ by beryllium-stimulated CD4
ϩ T cells
Activation requirements for optimal production of inflammatory cytokines are shown in Table I . Although BAL CD4 ϩ T line cells or APCs alone secreted very low levels of cytokines, the combination of T cells plus APCs produced a synergistic 3-to 10-fold increase in TNF-␣ and IFN-␥, but no change in IL-2. This beryllium-independent activation conceivably could represent an autologous MLR (AMLR), perhaps driven by recognition of self-MHC class II molecules. A similar degree of cytokine secretion occurred when BAL CD4 ϩ T line cells but not APCs alone were activated by BeSO 4 . This beryllium-dependent response could result from self-presentation of BeSO 4 by T-T interactions or through limiting numbers of BAL-derived APCs that persisted in the T cell line. Of importance, beryllium-dependent activation of BAL CD4 ϩ T cells with added APCs resulted in the superoptimal production of IFN-␥, TNF-␣, and IL-2 (Table I) .
More specifically, BAL CD4 ϩ T cells were stimulated with 10 M BeSO 4 in the presence of EBV-transformed autologous APCs at a ratio of 1:1 for 3 days and the supernatants were collected and analyzed for Th1/Th2 cytokines using a quantitative CBA assay. BAL CD4 ϩ T cells (40,000/well) cultured in 0.2 ml of medium generated Ͼ30 ng/ml IFN-␥ and 1 ng/ml TNF-␣ by 72 h (Fig. 1B) . The normalized production of IFN-␥ and TNF-␣ was calculated to be Ͼ150 ng IFN-␥ and 5 ng TNF-␣ produced per 1 million BAL beryllium-stimulated CD4 ϩ T cells within 72 h. Along with production of IFN-␥ and TNF-␣, BAL CD4 ϩ T cells produced IL-2 at Ͼ3 ng per million T cells. IL-4, IL-6, and IL-10 were essentially undetectable following stimulation. Thus, beryllium-specific CD4 ϩ T cells showed a predominant Th1 cytokine profile with unexpectedly high levels of secreted IFN-␥ and TNF-␣. Surprisingly, IFN-␥ and TNF-␣ production by beryllium-stimulated T cells persisted for an extended period (12 wk in culture), when the cells were split with fresh medium containing exogenous IL-2 without washing out the residual beryllium (data not shown). These data suggested that chronic exposure to even low levels of beryllium caused persistent production of IFN-␥ and TNF-␣.
Phenotypic analysis of BAL CD4 ϩ T cells and EBV-transformed autologous APC
Cell surface molecules were analyzed by FACS with a focus on characterizing the beryllium-induced activation profile of surface markers on BAL T cells cultured ex vivo. In addition to having relatively high levels of ␣␤-TCR (87%), the resting CD3 ϩ CD4 ϩ BAL T cells were virtually 100% positive for CD45RO. Unstimulated BAL T cells also expressed high levels of MHC class II molecules, HLA-DR, -DP, and -DQ, as well as LFA-1 (CD11a) and ICAM-3 (CD50) (Fig. 2A) . Upon exposure to beryllium, BAL T cells showed distinct cell surface molecular changes that provided clear insight into their behavior and, potentially, avenues for therapeutic intervention. OX40 (CD134) and CD25 (IL-2R␣) were both at low levels in IL-2-supported resting culture, but dramatically increased to levels Ͼ90% positive within 24 h (CD25) and 48 h (OX40) in the presence of BeSO 4 and APCs. The activated BAL T cells maintained these high expression levels until at least 144 h, the last time point evaluated (Fig. 2B) . OX40L expression was not visible on T cells either before or after stimulation (data not shown). Costimulatory molecules B7-1 (CD80) and B7-2 (CD86), both of which were expressed on APCs at very high levels (Fig. 2C) , were differentially expressed and up-regulated on BAL T cells upon beryllium stimulation (Fig. 2B) . B7-1 was expressed at moderate levels before beryllium stimulation and rapidly increased to high levels within 24 h after beryllium exposure. B7-2, however, was already highly expressed on resting BAL T cells before stimulation (Fig.  2B) . Similar to the B7-1 pattern, resting BAL T cells had a moderate expression of the costimulation molecule CD28 on resting cells that increased strongly after 24 h of stimulation (Fig. 2B) . CTLA-4 (CD152) was not significantly expressed on BAL T cells (data not shown). Staining of T cells with annexin V and 7-aminoactinomycin D before and after beryllium stimulation documented survival rates typically observed for effector/memory T cells (data not shown) (34, 35) .
The EBV-transformed autologous APCs used for these studies were Ͼ95% CD19 ϩ , suggesting that they were predominantly B cells, with high levels of expression of LFA-1 (CD11a), MHC class II molecules, B7-1 and B7-2, and unlike the BAL T cells an alternative costimulation molecule, OX40L (Fig. 2C) .
Blocking LFA-1 prevented proliferation and dramatically reduced effector cytokine production
We used a series of mAb blocking experiments, summarized in Table II , to characterize the requirement and relative importance of particular cell surface molecules for proliferation and effector cytokine production of beryllium-specific BAL T cells. In the presence of anti-LFA-1 Ab, both proliferation and, to a lesser degree, secretion of cytokines (IFN-␥, TNF-␣, and IL-2) by berylliumactivated BAL T cells were inhibited in a dose-dependent manner (Fig. 3) . These data indicate that interactions between the adhesion/trafficking molecule LFA-1 and its ligands contributes to the activation of beryllium-specific T cells.
Blocking HLA-DP prevented proliferation and dramatically reduced effector cytokine production
The absolute requirement of MHC class II molecules for activation of beryllium-specific T cells was clearly documented using Ab blocking experiments. As shown in Fig. 4A , addition of anti-HLA-DP Ab blocked T cell proliferation in a dose-dependent manner, with complete inhibition at 20 g/ml, strongly reinforcing previous data showing that MHC class II molecules are critical for beryllium-specific proliferation of BAL T cells. Moreover, anti-DP Ab blocked IFN-␥ 53% and TNF-␣ and IL-2 by ϳ70% (Fig. 4B) . Interestingly, anti-HLA-DR Abs also had a blocking effect on proliferation of BAL T line cells (Fig. 4A) , but anti-DR Ab had virtually no effect on inhibition of cytokine secretion (Fig. 4B) . The anti-HLA-DR Ab used in these experiments reacts with a nonpolymorphic HLA-DR epitope (36 -38) and does not cross-react with HLA-DQ or HLA-DP molecules (38) . Moreover, we have independently confirmed that the anti-DR Ab does not cross-react with the Ag-binding/TCR recognition domains of either HLA-DP2 or HLA-DP4 by ELISA (data not shown).
FIGURE 3. Blocking BAL CD4
ϩ T cell response to beryllium by a mAb (clone HI111) specific for human LFA-1. A, Blocking BAL CD4 ϩ T cell proliferation to beryllium by anti-LFA-1. BAL CD4 ϩ T cells (40,000/ well in triplicate) were cultured with EBV-transformed autologous APCs at ratio of 1:1 with and without 10 M BeSO 4 for 72 h. Anti-human LFA-1 Ab at concentrations of 10 and 2 g/ml were added into cultures of T cells stimulated with beryllium in the presence of APCs for 72 h. Mouse IgG1 at 10 g/ml was used as isotype Ab control. T cell proliferation was determined by [ 3 H]thymidine incorporation for the last 6 h of the culture. The percent block of proliferation after addition of anti-LFA-1 Ab was calculated relative to that of the isotype control Ab. Significance was determined by Student's t test. B, Blocking Th1 cytokine production of berylliumstimulated BAL CD4 ϩ T cells by anti-LFA-1. TNF-␣ and IL-2 production (picograms per milliliter) were measured using the CBA method on supernatant samples collected from BAL CD4 ϩ T cell cultures in triplicate as described above. The percent block of cytokine production by anti-LFA-1 Ab was calculated relative to that of the isotype control Ab and significance was determined by Student's t test. ) were added into cultures of T cells stimulated with beryllium at Ab concentrations of 20 and 5 g/ml for 72 h. Mouse IgG1 at 20 g/ml served as isotype Ab control. B, Cytokine production (picograms per milliliter) was determined in triplicate using the CBA method. The supernatant samples were collected from T cell cultures as described above. The percent block after addition of Abs was calculated relative to that of the isotype control Ab. Significance was determined by Student's t test. 
Costimulation involved in beryllium-induced CD4 ϩ T cell activation: OX40/OX40L pathway plays a dominant role in proliferation
Memory T cells can proliferate and secrete cytokines after TCR engagement without CD28-mediated costimulation (39) , and the CD28 costimulation independence of BAL beryllium-specific T cells has previously been reported (25) . We demonstrated above that 98% of BAL beryllium-specific CD4 ϩ T line cells were of the CD45RO ϩ memory phenotype, responding to beryllium in the presence of autologous APCs by proliferation and secretion of high levels of IFN-␥ and TNF-␣. Although CTLA-4 was not present at an appreciable level on resting or beryllium-activated BAL T cells (data not shown), the level of CD28 on the BAL T cell population changed significantly (from 54 to 92%) for 24 h after beryllium stimulation before declining back to the resting distribution (Fig. 2B ). Similar to a previous report (25) , blockade of signaling through CD28 using soluble CTLA4-Ig to ligate B7-1 and B7-2 molecules on APCs had a relatively modest inhibition of proliferation (15%), IFN-␥ (19%) and IL-2 (23%) secretion, but little effect on TNF-␣ (Fig. 5B) . Moreover, addition of anti-CD28 Ab had no significant effect on activation (Fig. 5A) . These data suggest a relatively minor contribution of the CD28/B7 costimulation pathway on beryllium-induced T cell activation.
In contrast to the transient up-regulation of CD28, berylliumactivated T cells had long-lasting high levels of OX40 expression (Fig. 2B) , possibly implicating this costimulation pathway. Indeed, blockade of the OX40-OX40L interaction using anti-OX40L Ab resulted in complete (99%) inhibition of proliferation (Fig. 5, A  and B) . However, there was only a modest inhibitory effect of anti-OX40L Ab on IL-2 secretion (24%) and no detectable effect on IFN-␥ or TNF-␣ levels (Fig. 5C ). Similar to anti-CD28 Ab, anti-OX40 Ab also did not inhibit beryllium-induced T cell proliferation (Fig. 5A) . These findings suggest a dominant role of the OX40/OX40L costimulation pathway on beryllium-induced proliferation, but further indicate that cytokine release is relatively independent of costimulation by either of these pathways.
Discussion
Characterization of pathogenic T cells from patients with CBD has revealed that beryllium-specific CD4 ϩ T cells play a major role in initiating and perpetuating granulomatous inflammation (10, 11) . The results presented above demonstrate that activation of BAL CD4 ϩ T cells is a complex process, involving beryllium-dependent HLA-DP and HLA-DR-restricted stimulation through the TCR, partial dependence on the OX40/OX40L costimulation pathway, and involvement of cell-cell adhesion mediated through ligation of LFA-1. Moreover, activation may also be induced by beryllium-independent interactions between T cells and APCs, reminiscent of an AMLR involving MHC class II recognition. An inherent weakness of our system is the reliance on observations made using mass T cell culture in vitro to faithfully duplicate what occurs in vivo. That being said, in preliminary experiments, ex vivo BAL cells from CBD subjects express high levels of LFA-1 and up to 30% of direct ex vivo BAL CD4 ϩ T cells up-regulate OX40 expression by 72 h after beryllium exposure in culture (A. P. Fontenot, unpublished observation). These results indicate that our cultured BAL cell line retained at least two important characteristics of freshly isolated BAL T cells from additional CBD patients, and thus this line appears to be generally representative of beryllium-driven T cells.
Consistent with the severe granulomatous inflammation known to occur in lung tissue in CBD, the in vitro combination of beryllium, APCs, and BAL CD4 ϩ T cells induced strong proliferation responses; superoptimal concentrations of the secreted proinflammatory cytokines IFN-␥, TNF-␣, and IL-2; and up-regulation of numerous T cell surface markers that would promote T-T Ag presentation. Ab blocking experiments revealed that anti-HLA-DP or anti-LFA-1 Ab strongly reduced proliferation responses and, to a lesser extent, cytokine secretion by BAL CD4 ϩ T cells. In contrast, anti-HLA-DR or anti-OX-40L Ab mainly affected berylliuminduced proliferation responses with little impact on cytokines other than IL-2, thus implying that nonproliferating BAL CD4 ϩ T cells may still contribute to inflammation. Blockade with CTLA4-Ig had a minimal effect on proliferation and cytokine responses, confirming that activation was independent of B7/CD28 costimulation. Because T cell proliferation and secretion of proinflammatory cytokines appear to play a dominant role in the chronic inflammatory process that defines CBD, it would appear that Abs ϩ T cell proliferation to 10 M BeSO 4 in the presence of EBV-transformed autologous APCs at a ratio of 1:1 was repeated, with and without adding 25 and 10 g/ml anti-OX40L and CTLA4-Ig, respectively, for 72 h. Proliferation was expressed as net cpm above background. C, Blocking IL-2 production of beryllium-stimulated BAL CD4 ϩ T cells by both CTLA-4Ig and anti-OX40L. Cytokine production (picograms per milliliter) was determined in triplicate by the CBA method. The supernatant samples were collected from T cell cultures as described above. The percent block after addition of Abs was calculated relative to that of the isotype control Ab. Significance was determined by Student's t test.
specific for HLA-DP and LFA-1 would be well suited for further investigation as a therapeutic strategy for intervention in CBD as well as other hypersensitivity pneumonitides.
T cell proliferation to beryllium salt in vitro was beryllium specific and dose dependent (Fig. 1A) , and our analysis clearly excluded nonspecific T cell stimulation by other metal salts, although the molecular details of metal-protein interactions underlying the transport and delivery of metal ions to APCs during their early sensitization phase and the interaction of beryllium with HLA and TCR is still unclear (40) . The BeSO 4 dose-dependent T cell proliferation curve consistently showed a decreased maximal stimulation above the peak responsive concentration of 20 M BeSO 4 , but concentrations up to 80 M still showed almost 70% of the maximal response. These data are consistent with previous observations regarding beryllium toxicity to APCs (41) and suggest that beryllium-specific T cells are truly tolerant of high doses of BeSO 4 . Our later studies documented that BAL CD4 ϩ T cells retained the ability to secrete large amounts of IFN-␥ and continuously live for months under conditions in which exogenous IL-2 was added (Y. K. Chou, personal communication).
Our studies documented that the BAL CD4 ϩ T cell line was strongly polarized toward Th1, secreting detectable amounts of IFN-␥ even in the absence of beryllium stimulation (Table I ). In the absence of APCs, addition of beryllium increased secretion of IFN-␥ by Ͼ100-fold, directly suggesting T-T interactions play a role in maintaining the chronic milieu characteristic of CBD. In contrast, addition of beryllium to APCs alone resulted in no change in IFN-␥ and TNF-␣ production. However, IFN-␥ secretion increased 100-fold merely by culturing the T cells with autologous APCs at a 1:1 ratio, indicating a beryllium-independent activation reminiscent of an AMLR, perhaps involving recognition of self-MHC class II molecules. Unexpectedly, upon beryllium addition to a 1:1 culture ratio of T:APC, the activated T line cells produced an astounding 38,000 pg/ml secreted IFN-␥, as well as Ͼ1000 pg/ml TNF-␣ and 700 pg/ml IL-2. Importantly, in the absence of APCs no IL-2 secretion was observed, clearly documenting the requirement of APCs for the full activation profile of these BAL T cells.
The memory phenotype of BAL beryllium-specific T cells has been reported previously (16 -18) , and is confirmed by our staining data, with the vast majority of the CD4 ϩ T cells staining positive for CD45RO. The features of high-level expression of CD134 (OX40; upon stimulation) and HLA-DR, -DP, and -DQ on the cell surface and the ability to secrete extremely high levels of IFN-␥ all confirm that this beryllium-specific BAL CD4 ϩ T cell line was highly activated with a T effector/memory phenotype (42) (43) (44) . The survival of CD4 ϩ T effector/memory cells depends on their ability to produce IL-2, whereas cells producing only effector cytokines (e.g., IFN-␥) may be short-lived (45) . The level of CD25 (IL-2R␣) expression is considered to be a reflection of recent Ag stimulation and plays a crucial role in the regulation of T cell proliferation (46) . In the current study, we found that CD25 was very rapidly up-regulated during the course of stimulation with beryllium, with 5-10% of the resting cells expressing CD25, increasing to Ͼ90% within 24 h and remaining at an elevated level for at least 144 h. CD25 expression on the cell surface finally declined 2-3 wk after beryllium stimulation in direct correlation to the concentration of BeSO 4 depleted from the culture medium by serial dilution. T cell proliferation continued as long as IL-2 was added to the culture medium. Of possible diagnostic importance, these data suggest that CD25 can be used as a functional marker for BAL CD4 ϩ T cell activation and exposure to BeSO 4 .
CD80 (B7-1) and CD86 (B7-2) are members of the Ig supergene family and are coregulators of T cell activation through interactions with CD28 and CTLA-4 on T cells. These molecules are expressed on APCs as well as on activated CD4 ϩ cells at late stages after activation (47) . We found very high-level expressions of B7-2 even on resting BAL CD4 ϩ T cells, and B7-1 was dramatically up-regulated within 24 h upon beryllium stimulation (Fig. 2B) . Previous studies suggested that beryllium-specific memory CD4 ϩ T cells in blood continued to require CD28 costimulation for proliferation and cytokine responses, whereas BAL effector memory cells were functionally independent of CD28 costimulation (25) . One possibility that warrants further investigation is that constitutively high levels of B7-2 allow direct T:T costimulation between resident activated B7-2 high CD28 high BAL T cells and effector/memory B7-2 high CD28 low CD4 ϩ T cells recruited to the lung from the blood, with T-T interactions providing both the primary signal as well as costimulation. Ab blocking studies have clearly helped to identify the most important pathways for activation of BAL CD4 ϩ T cells. The ability of anti-HLA-DP to abolish proliferation as well as eliminate 70% of both IFN-␥ and TNF-␣ effector cytokine and IL-2 autocrine secretion point to the central role played by HLA-DP in T cell activation. Future studies will be directed at evaluating how beryllium and HLA-DP interact and further the molecular recognition of beryllium as an HLA-DP-restricted Ag. Blockade of LFA-1 interaction using mAb HI111 (48) consistently inhibited proliferation and IL-2 secretion by Ͼ50% and also significantly reduced secretion of IFN-␥ and TNF-␣. The known ligands of LFA-1 include ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50) (49 -52) . ICAM-1 and ICAM-2 are expressed on endothelium and have been implicated in leukocyte adhesion and transendothelial migration. ICAM-3 is exclusively present on T and B leukocytes where it appears to be important for the initial scanning of the APC surface by T cells, as well as playing a role in augmenting LFA-1-and ICAM-1-mediated adhesion and signaling via lowaffinity interactions (53) (54) (55) . It is noteworthy that ICAM-1, which has an ϳ10,000-fold higher affinity for LFA-1 than ICAM-3 (56) , is also up-regulated on BAL T cells upon APC plus beryllium exposure (data not shown).
A novel observation from this study is that OX40 expression by beryllium-stimulated CD4 ϩ T cells was strongly up-regulated within 24 -48 h after stimulation with beryllium and was maintained at high levels throughout the 144-h observation period (Fig.  2B ). This activation profile of BAL T cells upon BeSO 4 stimulation is similar to changes observed with peptide-Ag-activated CD4 ϩ T cells (57) and suggests that the engagement of OX40 with OX40L expressed on APCs may play a role in activation and increased survival of beryllium-specific memory T cells (58) . Interestingly, blockade with anti-OX40L Ab inhibited proliferation responses but not cytokine secretion by BAL CD4 ϩ T cells, suggesting an uncoupling of the cell cycle from cytokine production. This finding implies that interruption of the OX40/OX40L costimulation pathway might limit the number of beryllium-reactive T cells without affecting their secretion of inflammatory cytokines. A similar pattern showing inhibition of proliferation but not cytokine responses was observed using anti-HLA-DR Ab, and the possibility exists that BAL CD4 ϩ T cells may exhibit a unique activation pathway involving TCR ligation through HLA-DR with OX40/OX40L costimulation.
In summary, our data reinforce previous work concerning the central importance of HLA-DP in beryllium disease, with blockade of HLA-DP being the best approach to eliminate proliferation ability and cytokine production. The ability of anti-LFA-1 to partially inhibit these activities is also of potential therapeutic importance. Since T cell expansion and secretion of proinflammatory cytokines appear to play a dominant role in the chronic inflammatory process that defines CBD, it would appear that Abs specific for HLA-DP and LFA-1 would be well suited for further investigation as a therapeutic strategy for CBD.
